Cardiac function in pediatric Ewing sarcoma during and after treatment: A longitudinal study

Abstract

AbstractBackgroundWhile anthracycline therapy has been shown to improve outcomes in Ewing sarcoma, it may be associated with severe and even fatal cardiac dysfunction. We evaluated the burden and determinants of cardiac dysfunction in pediatric Ewing sarcoma (pES).MethodsThis retrospective study included children aged 0–18 years with pES treated at our center with the EFT 2001 protocol (anthracycline and cyclophosphamide containing regimen), with/without radiation therapy from January 2001 to December 2018. Cardiac dysfunction was defined as left ventricular (LV) ejection fraction with an absolute value <50%.ResultsAmongst 650 eligible patients (median age at diagnosis 12 years and median follow‐up duration 69 months), 85 (13%) developed cardiac dysfunction, at a median 13 months (range: 1–168 months). The cumulative incidence of cardiac dysfunction was 5.7% at 12 months, 12% at 2 years, 13% at 3 years, 14% at 5 years, and 15 % at 10 years. At a median follow‐up duration of 25 (range: 3–212) months, 21 (24.7%) patients had normalization of LV function, whereas nine (10.6%) patients died of cardiac causes. Older age at diagnosis (7–12 years OR 5.1, p = .01, 13–18 years, OR 3.9, p = .03), female sex (OR 2.3, p = .004), undernutrition (OR 2.9, p = .001), and chest wall location (OR 8.7, p = .08) were risk factors for cardiac dysfunction.ConclusionsChildren with Ewing sarcoma have a high incidence of cardiac dysfunction, which continues to develop even years after therapy, underlining the need for life‐long surveillance. Undernourished children are at a higher risk for cardiac dysfunction and need stringent monitoring.